Ignite Creation Date:
2024-05-05 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 9:54 AM
Study NCT ID:
NCT00741819
Status:
COMPLETED
Last Update Posted:
2013-02-20
First Post:
2008-08-23
Brief Title:
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension PAH Subjects
Sponsor:
United Therapeutics
Organization:
United Therapeutics
Study Overview
Official Title:
An Open Label Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis Iloprost in Subjects With Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 24-month multi-center prospective open-label safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost Ventavis
Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline Week 6 Week 12 and Months 6 12 18 and 24 following initiation of treprostinil sodium
Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline Week 6 Week 12 and Months 6 12 18 and 24 following initiation of treprostinil sodium
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None